Jenny Hsiung

Born & raised in Taiwan. Committed to a lifelong career in healthcare. Passionate about biotech, tech, entrepreneurship, and leadership.

[Jenny Hsiung @TwBioBear]

The UK’s Plan to Sequence 100,000 Human Genomes http://t.co/nA1DgszT1j via @motherboard

[Jenny Hsiung @TwBioBear]

AbbVie's blockbuster hep C approval puts it toe to toe with Gilead http://t.co/f7Ws3zZOrJ

[Jenny Hsiung @TwBioBear]

ImmunoGen plummets as its Roche-partnered cancer drug comes up short http://t.co/1KfMMe3pwj

[Jenny Hsiung @TwBioBear]

Experiment with Organizational Change Before Going All In - @HarvardBiz http://t.co/mhDGrt9gDl

[Jenny Hsiung @TwBioBear]

We Should Be Protesting, Too @HuffPostBlog http://t.co/CrN2MllwCK via @HuffPostPol

[Jenny Hsiung @TwBioBear]

Why Hong Kong's #OccupyCentral Used Nonviolent Action as Tactic http://t.co/fbmn8I3UzH via @HuffPostPol

[Jenny Hsiung @TwBioBear]

Big Pharma's Money Ties To Doctors Revealed. Kind Of http://t.co/Qx7CBRJo9U via @HuffPostBiz http://t.co/Qx7CBRJo9U

[Jenny Hsiung @TwBioBear]

前苹果副总裁：如果你做的事情毫不费力，就是在浪费时间 http://t.co/TLPqNP09k5

[Jenny Hsiung @TwBioBear]

香港怎麼了
http://t.co/V6iFaPQaLl

[Jenny Hsiung @TwBioBear]

新藥授權順利 智擎登漲停板 http://t.co/J828S4ejIV via @tw_chinatimes

[Jenny Hsiung @TwBioBear]

Biotech IPOs: ProQR soars and Foamix thuds amid a volatile market - FierceBiotech: http://t.co/nauYEM38xD

[Jenny Hsiung @TwBioBear]

Struggling Merck KGaA plans blockbuster R&D campaign for biosimilars, pact for PD-L1 - FierceBiotech: http://t.co/KjgHExVm1I

[Jenny Hsiung @TwBioBear]

6新藥＋9醫材 Si2C潛力新秀出列 - 中時電子報 http://t.co/sDJ3W2KmUt via @tw_chinatimes

[Jenny Hsiung @TwBioBear]

Five Things People Do to Hurt Their Careers -- And How to Stop Doing Them @HuffPostBlog http://t.co/w0GPr8rw7t via @HuffPostWomen

[Jenny Hsiung @TwBioBear]

Alibaba Raises IPO Price Range http://t.co/jPTY5nfGH5

[Jenny Hsiung @TwBioBear]

The Second Life of Alnylam and Its Nearly Discredited Gene Therapy http://t.co/zk25TYxw8j >@TechReview

[Jenny Hsiung @TwBioBear]

http://t.co/RBrtid6Mjl

[Jenny Hsiung @TwBioBear]

Roche abandons another Fragile X R&D program after PhII trials flunk out - FierceBiotech: http://t.co/7q1YAZitvM

[Biotechnology @Biotechnology]

Shenzhen Beike Biotechnology Co. Ltd., Altor BioScience Corporation Strike $200 Million Cancer Deal: http://t.co/qVcn2GgPZQ

[Jenny Hsiung @TwBioBear]

OrbiMed Advisors banks $325M for a new round of Asian biotech bets - FierceBiotech: http://t.co/C3meXjjSGf